search

nlplab / brat

brat rapid annotation tool (brat) - for all your textual annotation needs
http://brat.nlplab.org
Other
1.81k stars 509 forks source link

Lock-up on broken annotation #699

Closed spyysalo closed 12 years ago

spyysalo commented 12 years ago

Trying to open the following document in brat causes a UI lock-up with the error

Unknown error: eventWithoutTrigger

.txt:

Novel therapies for inflammatory bowel disease.
Looking back at successes and failures in newer approaches to treating IBD, it is tempting--although still difficult--to draw conclusions about pathogenesis.
When a therapy proves effective, do clinicians truly know how it works?
Even with a therapy as specific as anti-TNF antibody, it is not clear if the benefit is attributable to simple binding and clearance of TNF-alpha or to binding on the cell surface and subsequent deletion of the activated macrophage.
When a drug appears to be less effective than preclinical models suggest, can failures in effectiveness from delivery or dosing be differentiated?
The disappointing results of clinical trials with IL-10--so at odds with the prediction of benefit from animal models--bring into question the validity of those models as well as the soundness of design of the clinical trials on which efficacy of IL-10 is judged.
The variability of response even to the most narrowly targeted agents suggests that these diseases are far more heterogeneous in humans than in their murine counterparts.
Clinicians are only just beginning to recognize subclinical markers of response, and it may soon be possible to predict response on the basis of genetic composition.
For the moment, however, the field of pharmacogenetics is embryonic.
Challenges in developing new therapeutic strategies include not only identifying novel agents, but also improving the definitions of clinical endpoints and defining efficacy at the biologic level.
Only through considered evaluation of clinical evidence may clinicians determine which therapies should remain novelties and which should become an accepted part of the armamentarium.

.ann

T1      Other 20 46     inflammatory bowel disease
T2      Other 119 122   IBD
T3      Other 192 204   pathogenesis
T4      Protein_family_or_group 313 330 anti-TNF antibody
T5      Protein_molecule 414 423        TNF-alpha
T6      Cell_component 445 457  cell surface
T7      Cell_natural 489 509    activated macrophage
T21     Cell_natural 499 509    macrophage
T8      Other 557 575   preclinical models
T9      Protein_molecule 708 713        IL-10
T10     Multicellular_organism_natural 762 775  animal models
T11     Other 868 883   clinical trials
T12     Protein_molecule 905 910        IL-10
T13     Multicellular_organism_natural 1051 1057        humans
T14     Multicellular_organism_natural 1072 1091        murine counterparts
T15     Other 1141 1160 subclinical markers
T16     Other 1238 1257 genetic composition
T17     Other 1297 1313 pharmacogenetics
T18     Other 1357 1379 therapeutic strategies
T19     Multicellular_organism_natural 1585 1595        clinicians
T20     Other 1694 1707 armamentarium
T22     Positive_regulation 355 362     benefit
A21     CL E1 L3
A11     KT E1 Gen-Other
A31     Manner E1 Neutral
A41     Polarity E1 Positive
A51     Source E1 Current
T23     Positive_regulation 366 378     attributable
A22     CL E2 L3
TK2     KT-Cue 348 350  if
A12     KT E2 Investigation
A32     Manner E2 Neutral
A42     Polarity E2 Positive
A52     Source E2 Current
A23     CL E3 L3
A13     KT E3 Investigation
A33     Manner E3 Neutral
A43     Polarity E3 Positive
A53     Source E3 Current
T25     Binding 389 396 binding
A24     CL E4 L3
A14     KT E4 Gen-Other
A34     Manner E4 Neutral
A44     Polarity E4 Positive
A54     Source E4 Current
T26     Negative_regulation 401 410     clearance
A25     CL E5 L3
A15     KT E5 Gen-Other
A35 Manner E5 Neutral
A45 Polarity E5 Positive
A55 Source E5 Current
A26 CL E6 L3
A16 KT E6 Investigation
A36 Manner E6 Neutral
A46 Polarity E6 Positive
A56 Source E6 Current
A27 CL E7 L3
A17 KT E7 Investigation
A37 Manner E7 Neutral
A47 Polarity E7 Positive
A57 Source E7 Current
T29 Cell_adhesion 430 437   binding
A28 CL E8 L3
A18 KT E8 Gen-Other
A38 Manner E8 Neutral
A48 Polarity E8 Positive
A58 Source E8 Current
T30 Negative_regulation 473 481 deletion
A29 CL E9 L3
A19 KT E9 Gen-Other
A39 Manner E9 Neutral
A49 Polarity E9 Positive
A59 Source E9 Current
T31 Physiological_process 489 498   activated
A210    CL E10 L3
A110    KT E10 Gen-Other
A310    Manner E10 Neutral
A410    Polarity E10 Positive
A510    Source E10 Current
T32 Positive_regulation 893 901 efficacy
A211    CL E11 L3
TK11    KT-Cue 914 920  judged
A111    KT E11 Investigation
A311    Manner E11 Neutral
A411    Polarity E11 Positive
A511    Source E11 Current
E11 Positive_regulation:T32 Cause:T12 Cue:TK11
E10 Physiological_process:T31 Theme:T21
E9  Negative_regulation:T30 Theme:T7
E8  Cell_adhesion:T29 Theme:T4 Theme:T6
E5  Negative_regulation:T26 Cause:E4 Theme:T4
E4  Binding:T25 Theme:T4 Theme:T5
E7  Positive_regulation:T28 Cause:E9 Theme:E1 Cue:TK2
E6  Positive_regulation:T27 Cause:E7 Theme:E1 Cue:TK2
E1  Positive_regulation:T22 Cause:T4
E3  Positive_regulation:T24 Cause:E5 Theme:E1 Cue:TK2
E2  Positive_regulation:T23 Cause:E4 Theme:E1 Cue:TK2
spyysalo commented 12 years ago

No longer locking up as of 80b661b69c08c3411ce68c743434404fd033807d; closing this.